STAT4 is phosphorylated by JAK2, and we confirmed that the JAK2-inhibitor ruxolitinib was more cytotoxic at comparable micromolar concentrations than TMZ in two gliosarcoma cultures, meriting further exploration in preclinical models. This evidence concerns the gene JAK2 and gliosarcoma.